Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines
Sklarz, L.-M., Gladbach, Y. S., Ernst, M., Hamed, M., Roolf, C., Sender, S., Beck, J., Schütz, E., Fischer, S., Struckmann, S., Junghanss, C., Fuellen, G., Murua Escobar, H.Volume:
20
Journal:
Cancer Cell International
DOI:
10.1186/s12935-020-01431-4
Date:
December, 2020
File:
PDF, 1.41 MB
2020